TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28420471
Drug: Pv‐aCO2 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pv‐aCO2 combined with PLR directed therapy
Study: 28420471
Drug: Central venous
Normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central venous pressure (CVP) directed therapy
Study: 22092589
Drug: NobelActive(TM) implant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NobelActive(TM) implant
Study: 22092589
Drug: Brånemark implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implant
Study: 10224729
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment (PE-SIT)
Study: 8722217
Drug: Alpha-tocopherol 60
Normalized name: (+)-alpha-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol 60 mg/day
Study: 8722217
Drug: Alpha-tocopherol 200
Normalized name: (+)-alpha-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol 200 mg/day
Study: 1848679
Drug: Prophylactic ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic ganciclovir (5 mg/kg IV twice daily for two weeks, then five times per week until day 120)
Study: 22805300
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g fibrinogen concentrate
Study: 3828182
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion (control group)
Study: 19850684
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogens (CEE) daily
Study: 12932748
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (Genotropin, Pharmacia) starting at 0.8 IU for one month, then 1.6 IU for 5 months, followed by individual titration to normal levels for age.
Study: 17280527
Drug: Placebo treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment.
Study: 11101059
Drug: Twice-daily stavudine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily stavudine (40 mg) plus once-daily didanosine (400 mg) and nevirapine (400 mg)
Study: 11101059
Drug: Twice-daily stavudine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily stavudine (40 mg) plus twice-daily didanosine (200 mg) and nevirapine (200 mg)
Study: 8985029
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and razoxane (150 mg/m2 daily during radiotherapy, starting 5 days before first irradiation)
Study: 1728731
Drug: Perioperative antibiotics
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotics
Study: 9923817
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dolasetron daily plus 300 mg cimetidine four times daily
Study: 9923817
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dolasetron daily plus 600 mg rifampin daily
Study: 9923817
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dolasetron daily (control)
Study: 2254674
Drug: Ketanserin (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20‐40 mg three times a day)
Study: 31948475
Drug: Jianpishengsui (JPSS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpishengsui (JPSS) herbal formula cream
Study: 11682660
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily for 4 weeks
Study: 8206188
Drug: Implantable programmable
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable programmable insulin pumps (IMP)
Study: 31141505
Drug: Cinacalcet treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet treatment
Study: 28833652
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical vitamin C applied twice daily
Study: 27133311
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAPT) - aspirin plus clopidogrel plus cilostazol; cilostazol loading dose of 100 mg bid for 1 week
Study: 27133311
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel; no cilostazol
Study: 24469880
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ASA
Study: 23212718
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel
Study: 7049709
Drug: supidimide 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: supidimide 2 x 200 mg per day
Study: 6360575
Drug: Verapamil 160
Normalized name: verapamil 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 160 mg bd
Study: 6360575
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg qd
Study: 20350429
Drug: Endotracheal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal lavage (2-3 times daily)
Study: 30844848
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy
Study: 10417667
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (inactivated polio vaccine)
Study: 29192549
Drug: AMP XR-OS
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP XR-OS (15 mL)
Study: 29192549
Drug: Adderall XR
Normalized name: Adderall XR
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall XR (30 mg capsule)
Study: 30156314
Drug: Fosravuconazole L-lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosravuconazole L-lysine ethanolate (100 mg RVCZ, n = 101)
Study: 27374360
Drug: Leukocyte-platelet rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-platelet rich fibrin (L-PRF) with allogenous bone graft
Study: 12575567
Drug: Tongmai Yizhi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongmai Yizhi capsule (TMYZC)
Study: 2452123
Drug: 0.10 mg
Normalized name: povidone-iodine 0.10 mg in 1 mL TOPICAL SOLUTION [Povidone Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg of rIFN‐gamma administered daily for 28 days
Study: 2452123
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (0.25 mg and 0.10 mg of rIFN‐gamma)
Study: 29775141
Drug: Daily activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activities (Control)
Study: 30736102
Drug: Tailored exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored exercise protocol during hospitalization, 15 to 30 minutes daily, supervised by an exercise specialist.
Study: 26467316
Drug: Routine clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine clinical treatment
Study: 2946608
Drug: Danazol therapy
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol therapy
Study: 25199824
Drug: Medication (MED)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (MED)
Study: 27568513
Drug: Heroin-assisted treatment
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin-assisted treatment (HAT)
Study: 18281662
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1,000 mg/m(2) on days 1, 8, and 15 every 28 days
Study: 18281662
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m(2) every 28 days
Study: 8686718
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic treatment (oxacillin or vancomycin plus gentamicin)
Study: 31653175
Drug: Medication effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication effect score
Study: 29447787
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus P2Y12 inhibitor (DAPT)
Study: 17173219
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with metronidazole and azithromycin
Study: 11397720
Drug: Inogatran (low‐molecular‐mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (low‐molecular‐mass direct thrombin inhibitor)
Study: 2967187
Drug: Bisoprolol 10-20
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10-20 mg o.d.
Study: 2967187
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20-40 mg b.i.d.
Study: 12003381
Drug: Cyanoacrylate glue
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanoacrylate glue injection
Study: 20686410
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment (5-day course given monthly for 8 months)
Study: 15988425
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.2 mg/kg bolus followed by 0.5 mg/kg/hour for 2 hours)
Study: 15988425
Drug: Placebo (normal-saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal-saline infusion)
Study: 10389787
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia followed by IV patient-controlled analgesia with morphine
Study: 1653578
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg die) for 6 months
Study: 367979
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg per day for 12 months
Study: 367979
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg per day for 6 months
Study: 28947723
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rivaroxaban
Study: 8489836
Drug: Iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 270 mg I/ml
Study: 7946687
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 320 mg I/ml
Study: 29954183
Drug: Rifampin 15
Normalized name: rifampin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 15 mg/kg/d
Study: 29954183
Drug: All rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All rifampin doses
Study: 27052839
Drug: Uninflated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninflated balloon treatment (control group)
Study: 25179086
Drug: Melatonin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin supplementation (5 mg daily for 90 days)
Study: 24743802
Drug: D-cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (50 mg)
Study: 17578790
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of efavirenz therapy
Study: 15626320
Drug: 1.5 mg/mL
Normalized name: thymol 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/mL rhBMP-2
Study: 11409559
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of isotonic saline solution (control group)
Study: 16856319
Drug: Pea fiber
Normalized name: Pea fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea fiber diet (33 g pea fiber product/10 MJ)
Study: 16856319
Drug: Pea fiber
Normalized name: Pea fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea fiber added to breakfast (12 g/10 MJ) and lunch (15 g/10 MJ)
Study: 26089183
Drug: Encenicline 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline 0.9 mg
Study: 26089183
Drug: Encenicline 0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encenicline 0.27 mg
Study: 24008606
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Pycnogenol
Study: 21794974
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a history of intravesical therapy
Study: 17239987
Drug: 1320-nm Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1320-nm Nd:YAG laser therapy
Study: 23270285
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (SS)
Study: 12393770
Drug: Lactated Ringers
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringers solution (RL)
Study: 7925517
Drug: pimobendan (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimobendan (average 10.3 mg.day‐1, n = 119)
Study: 7925517
Drug: enalapril (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (average 10.7 mg.day‐1, n = 123)
Study: 2531972
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied local anaesthetic cream (EMLA)
Study: 28192673
Drug: Melatonin 100
Normalized name: melatonin 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 100 mg·day‐1
Study: 26317257
Drug: Any antiplatelet/anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antiplatelet/anticoagulant therapy
Study: 26317257
Drug: ACE inhibitors/angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors/angiotensin II antagonist therapy
Study: 26317257
Drug: Any method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any method to stop smoking, lipid lowering agents, antiplatelet and/or anticoagulation therapy, and any kind of exercise program
Study: 24340989
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.4 mg/kg/hr rocuronium bromide (esmeron) in group 1 (n = 14)
Study: 24340989
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of 0.15 mg/kg/hr esmeron in group 2 (n = 11)
Study: 26065566
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure treatment
Study: 31686255
Drug: High-power therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-power therapeutic ultrasound with neutral gel
Study: 12184352
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for back pain
Study: 25081728
Drug: Hepatectomy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatectomy combined with 'Jianpi Huayu Therapy' (treatment group)
Study: 11566656
Drug: Dairy product
Normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy product consumption >2.5 servings daily
Study: 11566656
Drug: Skim milk
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skim milk consumption >600 mg Ca/d
Study: 31115192
Drug: Routine supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine supportive care plus CIM intervention (nurse-led supportive care intervention using Complementary and Integrative Medicine)
Study: 15786902
Drug: Oral insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral insertion
Study: 29987109
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/d
Study: 23890686
Drug: Ecologically‐Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecologically‐Based Treatment (n=30)
Study: 19747427
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (240 mg in four doses)
Study: 15061347
Drug: Manual-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-assisted cognitive behavior therapy (MACT)
Study: 7495235
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus vitamin E [0.4 g (400 IU)/d; n = 52]
Study: 7495235
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (325 mg; n = 48)
Study: 7495235
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus vitamin E
Study: 27312203
Drug: DMARD combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD combinations or biologic agents
Study: 27312203
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy or steroid and DMARD combinations
Study: 21501494
Drug: L-lysine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine (6 g/day)
Study: 16131600
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (1.2 IU/day for men and 1.8 IU/day for women)
Study: 28877893
Drug: Bifidobacteria-supplemented formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteria-supplemented formula (107 CFU/g of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, B. longum subspecies infantis)
Study: 14597641
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg aliskiren
Study: 388083
Drug: Adriamycin chemotherapy
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin chemotherapy
Study: 30407039
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing integrated with Cognitive-Behavioral Therapy (MI-CBT)
Study: 16159704
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (group 1)
Study: 8874907
Drug: 80 micrograms.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micrograms. kg‐1 morphine
Study: 28851314
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (4 weeks of oral S-1 and a 2-week rest over 12 months)
Study: 23229932
Drug: High-efficiency OL-HDF
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-efficiency OL-HDF (subgroup with median substitution volume >17.4 L per session)
Study: 18586462
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of Zn supplementation (as Zn sulfate)
Study: 8166893
Drug: morphine/bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine/bupivacaine
Study: 24656609
Drug: Washout and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washout and re-initiation group (300 mg daclizumab HYP)
Study: 24656609
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment group
Study: 24656609
Drug: Treatment initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiation group
Study: 21525406
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with cisplatin 75 mg/m(2), epirubicin 75 mg/m(2) and paclitaxel (Taxol) 175 mg/m(2) (CEP) followed by concomitant radiotherapy (RT) and weekly cisplatin 40 mg/m(2)
Study: 8791030
Drug: 311C90 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 311C90 20 mg
Study: 25096769
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (0.5 mg/kg/min)
Study: 22101221
Drug: Carboplatin administered
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered by convection-enhanced delivery (CED)
Study: 9809131
Drug: Low-dose LAAM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose LAAM (165 mg/week)
Study: 7915916
Drug: IL‐1 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1 alpha treatment
Study: 23085134
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg orally)
Study: 1233219
Drug: Metoprolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (40 mg orally)
Study: 29428459
Drug: Ritonavir‐boosted protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir‐boosted protease inhibitor (PI) monotherapy
Study: 26698263
Drug: Atorvastatin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin combined with trimetazidine
Study: 21876312
Drug: Levamisole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (100 mg orally for 12 days)
Study: 18180678
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group, n=23)
Study: 10921543
Drug: Postpyloric paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpyloric paracetamol administration
Study: 10921543
Drug: Gastric paracetamol
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric paracetamol administration
Study: 10921543
Drug: Paracetamol pharmacokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol pharmacokinetic study
Study: 10921543
Drug: Opiate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate dose
Study: 8726596
Drug: Methylprednisolone, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, administered early
Study: 8726596
Drug: New pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pharmacologic agents (not specified)